Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01252771 · ClinicalTrials.gov registry record · Phase 4

Phosphate Kinetic Modeling 2

A Phase 4 study of ESRD and Hyperphosphatemia, sponsored by Fresenius Medical Care North America.

Completed
Registry status
Phase 4
Development phase
81
Enrollment target
1
Study location

NCT01252771: Completed Phase 4 study of ESRD and Hyperphosphatemia, sponsored by Fresenius Medical Care North America.

NCT01252771 is a Phase 4 study of ESRD and Hyperphosphatemia that has completed, run by Fresenius Medical Care North America. The registered enrollment target is 81 participants, below the 135-participant average among 13 other ESRD trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01252771, a Phase 4 study of ESRD and Hyperphosphatemia, has completed, sponsored by Fresenius Medical Care North America.

COMPLETED
Registry status
Phase 4
Development phase
81 participants
Enrollment target
1
Study location

Study Summary

The study aims to investigate the concept of computer based Phosphate Kinetic Modeling (PKM) in the hemodialysis patient population. This computerized algorithm model was developed as a tool to aid physicians in controlling a hemodialysis patient's phosphate level. Once a subject consents to participate in the study, the subject's dietary phosphate intake will be estimated by the modeling program and the appropriate dose of the phosphate binder calcium acetate (PhosLo) will be recommended accordingly. If necessary, the Ca++ concentration of the dialysate will be changed to remove any excess calcium absorbed as the result of an increase in the PhosLo prescription to control phosphorus.

Primary Outcome

The primary outcome variable is the change in serum phosphorus between a baseline period and the latest value of the intervention period.

Conditions Studied

Interventions

  • OTHER PKM Algorithm

Study Locations (1)

New York

  • Renal Research Insitutue - New York

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2010-09
Est. Completion 2011-12
Phase Phase 4

What the finished NCT01252771 record still lists

NCT01252771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 135-participant average among 13 other ESRD trials with a reported enrollment target (40% lower).

The record links to 2 conditions, with ESRD appearing as the primary indexed condition, and to 1 intervention - of which PKM Algorithm is the first listed.

NCT01252771 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01252771 about?

NCT01252771 is a clinical study titled "Phosphate Kinetic Modeling 2". The study aims to investigate the concept of computer based Phosphate Kinetic Modeling (PKM) in the hemodialysis patient population. This computerized algorithm model was developed as a tool to aid physicians in controlling a hemodialysis patient's phosphate level. Once a subject consents to partici...

What is the current status of trial NCT01252771?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2010-09. Estimated completion is 2011-12.

What conditions does trial NCT01252771 study?

This clinical trial studies the following conditions: ESRD, Hyperphosphatemia.

What interventions are being tested in trial NCT01252771?

The interventions under investigation include: PKM Algorithm (OTHER).

Who is sponsoring clinical trial NCT01252771?

This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01252771 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ESRD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01252771's enrollment target sits among peer trials

81 9th of 13 higher than 5 of 13 other ESRD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other ESRD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04966481 · 81 participants · Phase 3

    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

  • NCT05109429 · 81 participants · NA

    Developing a Clinical Outcome Assessment for Opioid Craving

  • NCT05112601 · 81 participants · Phase 2

    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • NCT05305911 · 81 participants · Phase 2

    Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01252771, the US trial registry maintained by the National Library of Medicine. NCT01252771 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.